Chapter 8: The Economics of Pharmacotherapeutics

S. healthcare system, tracing the evolution of health coverage from early fee-for-service models to modern managed care organizations (MCOs), including the establishment of Health Maintenance Organizations (HMOs) following the 1973 HMO Act and the subsequent growth of Preferred Provider Organizations (PPOs). Central to MCO strategies is the field of pharmacoeconomics, which employs specialized analyses—such as cost-benefit analysis, cost minimization analysis, cost-effectiveness analysis, and cost-utility analysis (utilizing Quality-Adjusted Life-Years, or QALYs)—to assess the overall value of drug interventions. These evaluations directly inform the composition of formularies, or preferred drug lists, which are developed and regularly revised by the multidisciplinary Pharmacy and Therapeutics (P&T) committee based on safety, efficacy, and cost data. To control rapidly increasing prescription drug spending, MCOs implement various utilization management tools: formularies are structured into tiered copayment systems to encourage the use of less costly generic products; generic substitution promotes the dispensing of bioequivalent drugs; and therapeutic interchange facilitates the switching between chemically distinct but therapeutically similar agents, often targeting high-cost "me too" drugs. Further restrictions include prior authorization requirements for expensive or nonpreferred medications, and step therapy protocols that mandate failure on a first-line drug before coverage is granted for a higher-tier alternative. Compliance among providers is monitored using metrics like generic prescribing percentages and per-member–per-month (PMPM) reports, with MCOs leveraging prescriber incentives, differential pharmacist reimbursement, and patient cost-sharing to influence behavior. Finally, the chapter addresses the growing role of health technologies like electronic prescribing (e-prescribing), which minimizes medication errors and verifies coverage in real time, the integration of Electronic Health Records (EHRs), and the increasing adoption of telehealth services to improve access and reduce costs. Contemporary economic challenges include managing the provisions of the Affordable Care Act and addressing the financial conflicts arising from manufacturer-issued copayment cards versus MCO-imposed copay accumulator programs.